Public demo intelligence report
This demo uses a real ClinicalTrials.gov record and only displays fields that are available from source data or clearly marked AI analysis.
Teva Pharmaceuticals USA conducted a Phase 3 clinical trial (NCT04729621) to evaluate the efficacy and safety of TVB-009P compared to Denosumab (Prolia®) in treating postmenopausal osteoporosis. The study involved 332 participants and was completed in June 2023.
AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.
Source URL: ClinicalTrials.gov
Source updated: Apr 18, 2024
Ingested: Jun 04, 2026
Internal sync: Jun 05, 2026
AI model: trialsignal-ai-v1
Normalized fields: validated
NCT ID
NCT04729621
Title
A Randomized, Double-Blind, Multinational, Multicenter Study to Compare Efficacy, Safety, and Immunogenicity of TVB-009P and Denosumab (Prolia®) in Patients With Postmenopausal Osteoporosis
Sponsor
Teva Pharmaceuticals USA
Status
COMPLETED
Phase
PHASE3
Condition raw
Osteoporosis, Postmenopausal
Condition normalized
Osteoporosis, Postmenopausal
Modality raw
monoclonal antibody
Modality normalized
monoclonal antibody
Target raw
TVB-009, Prolia®
Target normalized
TVB-009, Prolia®
Interventions
TVB-009, Prolia®
NCT identifier, sponsor, status, phase, condition, intervention and original registry URL remain visible in every report.
Premium reports separate protocol description, outcomes, eligibility, results, contacts and IP notes into readable sections.
The premium PDF export uses a branded board-report layout with provenance, taxonomy, executive snapshot and disclaimers.